Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AKBA | 8-K | neutral | 3/10 | Akebia Therapeutics disclosed the resignation of Nicholas Grund, Senior Vice President and Chief Commercial Officer, eff | Oct 14, 2026 |
| FAST | 8-K | bullish | 6/10 | Fastenal reported Q3 2026 EPS of $0.35, a 15.7% beat vs consensus of $0.30, on revenue of $2.463B (consensus $2.33B, +5. | Oct 14, 2026 |
| TRDA | 8-K | bullish | 6/10 | Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 | Oct 14, 2026 |
| CIFR | 8-K | bearish | 6/10 | Cipher Digital priced $850M of 0.00% convertible senior notes due 2032 (with a $150M greenshoe option) and concurrently | Oct 14, 2026 |
| BTLN | 8-K | bullish | 4/10 | Brightline Interactive received Nasdaq confirmation that it has regained compliance with the minimum $1.00 bid price rul | Oct 14, 2026 |
| MS | 8-K | neutral | 5/10 | Morgan Stanley reported Q3 2026 net revenues of $20.3B (+12% YoY) and EPS of $3.03 (+8% YoY), beating consensus estimate | Oct 14, 2026 |
| FFAI | 8-K | bullish | 7/10 | FFAI signed a definitive agreement on October 12, 2026, for FFR to acquire FFAI's full robotics business at an agreed va | Oct 14, 2026 |
| FFR | 8-K | mixed | 7/10 | FF EAI Robotics Ecosystem Inc. (FFR) entered into a definitive transaction agreement to acquire the robotics business of | Oct 14, 2026 |
| STT | 8-K | bullish | 6/10 | State Street reported strong Q3 2026 results with EPS of $3.69, beating consensus of $3.63 by 1.6%, and total revenue of | Oct 14, 2026 |
| KPTI | 8-K | neutral | 3/10 | Karyopharm Therapeutics filed an 8-K to extend the forbearance period under its existing Forbearance Agreement and Limit | Oct 14, 2026 |
| AQST | 8-K | bullish | 6/10 | Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal f | Oct 14, 2026 |
| ETON | 8-K | bullish | 6/10 | Eton Pharmaceuticals entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVA | Oct 14, 2026 |
| SOTK | 8-K | mixed | 5/10 | Sono-Tek reported fiscal Q2 2027 results with net sales up 1% YoY to $5.23M, but operating income declined 9% and net in | Oct 14, 2026 |
| XERS | 8-K | neutral | 3/10 | Xeris Biopharma filed patent infringement lawsuits against Torrent Pharma, Cycle Pharmaceuticals, Rising Pharma, and rel | Oct 14, 2026 |
| ENTG | 8-K | neutral | 2/10 | Entegris announced a quarterly cash dividend of $0.10 per share, payable on November 18, 2026, to shareholders of record | Oct 14, 2026 |
| COMP | 8-K | neutral | 2/10 | Compass announced the resignation of board member Charles Phillips (effective Oct 9, 2026) and the appointment of former | Oct 14, 2026 |
| XTIA | 8-K | neutral | 3/10 | XTI Aerospace appointed Dr. Allan Evans, CEO of Unusual Machines (UMAC), as a Class I director and Chairman of the Board | Oct 14, 2026 |
| UTHR | 8-K | bullish | 7/10 | United Therapeutics (UTHR) entered into a comprehensive settlement agreement with Liquidia Technologies, resolving all p | Oct 14, 2026 |
| RRC | 8-K | neutral | 3/10 | Range Resources filed a preliminary Q3 2026 update, reporting an expected total gain on derivatives of $58.1 million and | Oct 14, 2026 |
| BAC | 8-K | bearish | 6/10 | Bank of America reported Q3 2026 GAAP net income of $6.9B ($0.91 EPS), which included a $1.2B regulatory settlement char | Oct 14, 2026 |
| ACN | 8-K | bullish | 6/10 | Accenture hosted its FY27 Investor Day, reporting FY26 results that exceeded original guidance and outlining a multi-yea | Oct 14, 2026 |
| NFG | 8-K | bullish | 7/10 | National Fuel Gas Company (NFG) announced a plan to separate into two independent, publicly traded companies via a tax-f | Oct 14, 2026 |
| BLK | 8-K | bullish | 6/10 | BlackRock reported Q3 2026 adjusted diluted EPS of $15.93, a 38% YoY increase, on total revenue of $7.752B (+19% YoY). A | Oct 14, 2026 |
| QNRX | 8-K | bullish | 5/10 | Quoin Pharmaceuticals announced that its lead product candidate QRX003 received Orphan Drug Designation from the EMA for | Oct 14, 2026 |
| VSTM | 8-K | bullish | 7/10 | Verastem reported preliminary Q3 2026 net product revenue of ~$23.9-24.1M (vs $11.2M YoY), announced CEO Dan Paterson's | Oct 14, 2026 |
| FXAC | 8-K | bearish | 5/10 | FortuneX Acquisition Corp (FXAC) amended its business combination agreement with WT Realty Group Inc., reducing the aggr | Oct 14, 2026 |
| AITX | 8-K | neutral | 3/10 | AITX subsidiary RAD secured an order for seven ROSA security units from a new municipal customer in a major Midwest city | Oct 14, 2026 |
| LQDA | 8-K | mixed | 7/10 | Liquidia entered into a global settlement with United Therapeutics (UTC) resolving all six pending lawsuits, including p | Oct 13, 2026 |
| NWSA | 8-K | neutral | 3/10 | News Corp filed a routine 8-K to disclose daily buy-back activity under its existing $1 billion share repurchase program | Oct 13, 2026 |
| TRFA | 8-K | neutral | 3/10 | Trafalgar International filed an 8-K to adopt Amended and Restated Articles of Incorporation, which comprehensively rest | Oct 13, 2026 |